Novel NLRP3 Inhibitors for Steroid Resistant Asthma

用于治疗类固醇耐药性哮喘的新型 NLRP3 抑制剂

• 批准号: nhmrc : 1118973
• 负责人: Prof Matthew Cooper
• 金额: $ 63.26万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-nlrp3-inhibitors-resistant-asthma/946360
• 关键词: Novel; NLRP3; Inhibitors; Steroid; Resistant

Asthma causes 40,000 hospitalisations p.a. with 5-10% of asthmatics having severe steroid resistant asthma, a common and debilitating disease, where current treatments do not work. Effective therapies are urgently required. Based on our research, we have novel molecules showing high level of efficacy in models of severe steroid resistant asthma. These molecules will be further investigated to deliver a drug candidate for commercialisation within 3 years.

哮喘每年导致4万人住院。5-10%的哮喘患者患有严重的类固醇抵抗性哮喘，这是一种常见的使人衰弱的疾病，目前的治疗方法对此不起作用。迫切需要有效的治疗方法。基于我们的研究，我们有新的分子在严重的类固醇抵抗性哮喘模型中显示出高水平的疗效。这些分子将被进一步研究，以在3年内提供商业化的候选药物。